A phase I clinical trial in patients, with incurable metastatic carcinoma, lymphoma, or sarcoma (NCT01644968), using 9B12, a murine agonistic anti-human OX40 mAb, demonstrated that OX40 mAb treatment induced proliferation of CD4+ and CD8+ T cells and NK cells, enhanced production of IFN-γ by CD8+ T cells, boosted T- and B-cell antitumor reactivity, and increased memory T cells (Curti et al., 2013). This evidence concerns the gene CD8A and sarcoma.